It remains controversial if radical prostatectomy or definitive radiation therapy produces equivalent outcomes in high-risk localized prostate cancer.
We queried The Surveillance, Epidemiology, and End Results (SEER) database for those who received upfront surgery or who were recommended for surgery but instead received radiation. Inverse probability of treatment weighing was used to adjust for covariate imbalance and the weighted Cox proportional hazards model was used to estimate the effects of treatment groups on survival. A meta-analysis was performed to pool estimates from published studies.
Among eligible 62 533 patients, 59 540 had upfront surgery and 2993 patients had upfront radiotherapy. EBRT + BT was associated with a superior cancer-specific survival (CSS) compared with surgery or EBRT alone (HR, 0.55, 95% CI, 0.3-1.0; HR, 0.49, 95% CI, 0.24-0.98, respectively), whereas EBRT was associated with an inferior overall survival (OS) compared with surgery (HR, 1.46, 95% CI, 1.16-1.8). Radiotherapy (EBRT ± BT) was inferior to surgery by OS (HR, 1.63, 95% CI, 1.13-2.34) in patients ≤ 65 years, and was superior to surgery by CSS in patients > 65 years (HR, 0.69, 95% CI, 0.49-0.97). The meta-analysis showed consistent results.
EBRT + BT was associated with a significantly better prostate CSS compared with surgery or EBRT. EBRT alone was inferior to surgery by OS.
Cancer medicine. 2019 Nov 07 [Epub ahead of print]
Ming Yin, Jing Zhao, Paul Monk, Douglas Martin, Edmund Folefac, Monika Joshi, Ning Jin, Amir Mortazavi, Claire Verschraegen, Steven Clinton
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Biomedical Statistics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Division of Hematology and Oncology, Penn State University Hershey Cancer Institute, Hershey, PA, USA.